Evidence map›Paper›PMID 11855737›Full record

ArticleMolecular and cellular biochemistry2001

Bilirubin binding to normal and modified human erythrocyte membranes: effect of phospholipases, neuraminidase, trypsin and CaCl2.

I Rashid, M Owais, S Tayyab

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

I RashidInterdisciplinary Biotechnology Unit, Aligarh Muslim University, India.
M Owais
S Tayyab
Aligarh Muslim University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Binding of bilirubin to human erythrocyte membranes was studied after various enzymatic treatments as well as calcium loading. Whereas phospholipase D treatment of erythrocyte membranes resulted in 23% increase in bilirubin binding, phospholipase C-treated membranes showed remarkable enhancement in bilirubin binding. Polar head groups in general and negatively charged phosphate moieties, in particular, of phospholipids of the membrane appear to inhibit a large amount of bilirubin from binding to the membranes. Neuraminidase treatment of the membranes also led to a slight increase in bilirubin binding as compared to untreated membranes. Membrane proteins and carbohydrates seem to play significant regulatory role in bilirubin binding. However, no direct correlation was found between the increase in bilirubin binding and the amount of carbohydrate released upon tryptic digestion of membranes. Increase in bilirubin binding to trypsin-treated membranes can be ascribed to the increase in free bilirubin concentration in the incubation mixture as a result of tryptic hydrolysis of albumin by the membrane-bound tryptic activity. Calcium-loaded erythrocyte membranes also showed remarkable increase in bilirubin binding as a result of negative charge shielding and calcium-induced hydrophobic aggregation. Taken together, these results suggest the inhibitory role of polar head groups of phospholipids (phosphate in particular), carbohydrate and sialic acid in the binding of bilirubin to erythrocyte membranes.

Indexed as

BilirubinCalcium ChlorideCarbohydrate MetabolismElectrophoresis, Polyacrylamide GelErythrocyte MembraneHumansKineticsNeuraminidasePhospholipase DProtein BindingTime FactorsTrypsinType C PhospholipasesBilirubinCalcium ChlorideNeuraminidasePhospholipase DTrypsinType C Phospholipases

Identifiers

PMID11855737
OpenAlexW226814975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.